Attorney Docket No. A-58117/WHD

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner: Fitzgerald

BREECE, et al.

Group Art Unit: 1812

Serial No. 08/080,354

San Francisco, California

Filed: 21 June 1993 January 6, 1994

For: PROCESS FOR

PRODUCING RELAXIN

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231 on January 6, 1994

RESPONSE TO COMMUNICATION

Commissioner of Patents and Trademarks Washington, DC 20231

ATTN: Robert J. Hill, Jr.

Supervisory Patent Examiner

Group 1800

Sir:

In response to the Communication, Paper No. 7 mailed November 10, 1993, please find enclosed:

> A substitute paper copy of the Sequence Listing (pages No. 35-51).

- A substitute computer-readable form of the Sequence Listing.
- 3. A copy of the Notice to Comply with Requirements.
- 4. A Petition for Extension of Time to respond to the Notice.

Please amend the specification to delete the existing Sequence Listing (pages numbered 1-21, immediately preceding the claims) and substitute therefor the enclosed Sequence Listing.

The paper copy of the Sequence listing has been rearranged to place the sequences in numerical order. The floppy disk has been similarly corrected and also has been corrected so that printing of the nucleotide sequences and their numbers occurs on one line.

The substitute paper copy and the computer-readable copy are identical and do not contain new matter.

We are also enclosing new copies of the claims and abstract which have been renumbered as pages 52-56 of the application.

In view of the foregoing, this application is believed to be in condition for allowance and action to that end is requested. If a telephone conference will facilitate the

handling of the application, the Examiner is requested to telephone the undersigned at 415-781-1989.

The Commissioner is hereby authorized to charge any fee which may be required, including extension fees, or credit any overpayment to Deposit Account No. 06-1300 (Order No. A-58117/WHD). One copy of this sheet is enclosed.

Respectfully submitted,

FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT

BY

Walter H. Dreger Reg. No. 24,190

Suite 3400 Four Embarcadero Center San Francisco, California 94111-4187 Telephone: (415) 781-1989

πουμεστίμε εμφοράς καυγοκ κατας κόμε σεγοράςε μιες μοσυσεέ
The nucleotide and/or amino acid sequence contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 CFR 1.821
- 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on
paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
Submitted as required by 37 Crk 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted.
However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been
found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6 The paper seem of the re
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Applicant must provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence
Listing"
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
A statement that the content of the paper and computer readable copies are the same
and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or $1.821(f)$ or $1.821(g)$ or $1.825(b)$ or $1.825(d)$
For questions regarding compliance with these requirements, please contact:

CHIREMENTS NOT DATENT APPIN PATIONS CONTAINING

Please return a copy of this notice with your response.

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400